This CME program will highlight the use of FcRn blockers in the treatment of patients with generalized myasthenia gravis (gMG). The expert faculty, Dr. Miguel Chuquilin, will first review the disease burden and unmet needs of patients with gMG and specific QoL measures. Following, he will analyze the current clinical trial data for gMG therapeutics and use of minimal symptom expression (MSE), in order to measure disease activity and guide progress towards treatment goals. Lastly, Dr. Chuquilin will discuss the development of individualized treatment plans for FcRn blockers, including the role of pre-filled self-injection routes of administration to improve patient outcomes.
Neurologists and other healthcare providers who care for patients with gMG.
Review the disease burden and unmet needs of patients with gMG and specific QoL measures including minimal symptom expression (MSE)
Evaluate the current clinical trial data for gMG therapeutics and use of MSE in order to measure disease activity and guide progress towards treatment goals
Develop individualized treatment plans for FcRn blockers including the role of pre-filled self-injection routes of administration to improve outcomes
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.
| Faculty | Relationship Identified With: |
| Miguel Chuquilin, MD | Consultant/Advisor: Alexion Pharmaceuticals, Inc.; Amgen Inc.; Janssen Pharmaceuticals; UCB |
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC, Chelsey Simonds and Nicole McMenamin hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM.
Participants should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from argenx.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and argenx do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
